Skip to main content

Finasteride News

FDA Approves Entadfi (finasteride and tadalafil) as a New Treatment for Benign Prostatic Hyperplasia

MIAMI, Dec. 13, 2021 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, a...

FDA Medwatch Alert: MasterPharm, LLC. Issues Voluntary Nationwide Recall of Finasteride Plus 1.25mg Due to the Presence of an Undeclared Antihypertensive Drug

May 11, 2020 – MasterPharm, LLC. is voluntarily recalling 1 lot of Finasteride Plus 1.25mg, capsules to the consumer level. The Finasteride Plus capsules have been found to contain undeclared...

FDA Medwatch Alert: 5-alpha reductase inhibitors (5-ARIs): Label Change - Increased Risk of Prostate Cancer

Drugs in the 5-ARI class include finasteride and dutasteride. These drugs are marketed under the brand-names Proscar, Propecia, Avodart, and Jalyn ISSUE: FDA notified healthcare professionals that...

FDA Medwatch Alert: Citalopram And Finasteride by Greenstone: Recall - Possible Mislabeling

ISSUE: Greenstone LLC announced a recall of medicines with lot number FI0510058-A on the label. Bottles labeled as Citalopram (used to treat depression) may contain Finasteride (used for the...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Benign Prostatic Hyperplasia (BPH)

Finasteride patient information at Drugs.com